United States v. Robert Ray Courtney

CourtCourt of Appeals for the Eighth Circuit
DecidedApril 5, 2004
Docket02-4083
StatusPublished

This text of United States v. Robert Ray Courtney (United States v. Robert Ray Courtney) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Robert Ray Courtney, (8th Cir. 2004).

Opinion

United States Court of Appeals FOR THE EIGHTH CIRCUIT ________________

No. 02-4083 ________________

United States of America, * * Appellee, * * Appeal from the United States v. * District Court for the * Western District of Missouri. Robert Ray Courtney, * * [PUBLISHED] Appellant. *

________________

Submitted: September 9, 2003 Filed: April 5, 2004 ________________

Before LOKEN, Chief Judge, McMILLIAN and HANSEN, Circuit Judges. ________________

HANSEN, Circuit Judge.

Robert Ray Courtney, a pharmacist, diluted several chemotherapy drugs before distributing them for administration to cancer patients. His profit-making scheme was detected when one of the doctors who bought from Courtney became suspicious that he was selling more chemotherapy drugs than he was buying from the manufacturers. The doctor took a dose of Taxol that Courtney had recently supplied for one of her patients and sent it to a lab for analysis. The lab reported that it contained 32% of the Taxol it was supposed to contain. The doctor then met with FDA and FBI agents. The federal agents tested seven additional samples of Gemzar and Taxol that Courtney had supplied for the doctor’s patients. They found that the doses contained from 17% to 50% of the chemotherapy drugs they were supposed to contain. The federal agents then had the doctor order doses of Platinol, Zofran, Gemzar, Taxol, and Paraplatin from Courtney using fictitious patient names. Lab testing revealed that these samples contained from 0% to 65% of the dosages that the doctor had ordered and that Courtney had represented they contained.

Authorities executed a search warrant at Courtney’s pharmacy, and he was arrested and indicted. He pleaded guilty to eight counts of product tampering causing serious bodily injury, in violation of 18 U.S.C. § 1365(a)(3) (2002), and twelve counts of adulterating or misbranding a drug, in violation of 21 U.S.C. § 331(k).

As part of his written plea agreement, Courtney stipulated to the following factual basis for the eight product-tampering offenses. He diluted a dose of Taxol for each of two patients, resulting in serious bodily injury to them when it was administered. He diluted a dose of Gemzar for each of six patients, resulting in serious bodily injury to them when it was administered. Courtney stipulated to the following factual basis for the twelve adulterating/misbranding counts. When the doctor ordered the chemotherapy for the fictitious patients, Courtney supplied six doses of Gemzar and Taxol, each of which he had adulterated by dilution but mislabeled as undiluted.

Courtney also stipulated to the following crimes beyond his twenty offenses of conviction. As to the eight patients who were named in the product-tampering charges, he diluted fifty additional doses of Gemzar and Taxol that were administered to them. As to twenty-six more patients who were not identified in the indictment, Courtney diluted 102 doses of Gemzar and Taxol that were administered to them. Courtney also admitted that he had sold stolen Gemzar and Taxol, that he had diluted

2 Platinol and Paraplatin, and that he had caused false Medicare claims to be filed by not disclosing his tampering to the physicians to whom he distributed diluted drugs.

The district court1 made the following Sentencing Guidelines calculations. Each of the eight product-tampering convictions was placed in a single-count group because each involved a different victim. See U.S. Sentencing Guidelines Manual (USSG) § 3D1.2(b) (2000). Each single-count group carried an adjusted offense level of thirty-five: a base offense level of twenty-five, see USSG § 2N1.1(a), a four-level enhancement for causing life-threatening bodily injury, see USSG § 2N1.1(b)(1)(A), a two-level enhancement because the victims were vulnerable, see USSG § 3A1.1(b)(1), a two-level enhancement because there was a large number of vulnerable victims, see USSG § 3A1.1(b)(2), and a two-level enhancement for abuse of a position of trust and use of a special skill, see USSG § 3B1.3.

The twelve adulterating/misbranding convictions were grouped together. The group carried an adjusted offense level of twenty-four: a base offense level of six, see USSG § 2N2.1(a), an eight-level enhancement for the value of the diluted drugs, see USSG § 2F1.1(b)(1)(I), a two-level enhancement for more than minimal planning and a scheme to defraud more than one victim, see USSG § 2F1.1(b)(2), a two-level enhancement for the risk of serious bodily injury, see USSG § 2F1.1(b)(7)(A), a two- level enhancement because the victims were vulnerable, see USSG § 3A1.1(b)(1), a two-level enhancement because there was a large number of vulnerable victims, see USSG § 3A1.1(b)(2), and a two-level enhancement for abuse of a position of trust and use of a special skill, see USSG § 3B1.3.

Under the grouping rules, the combined offense level was determined by beginning with the offense level, thirty-five, for the group with the highest offense

1 The Honorable Ortrie D. Smith, United States District Judge for the Western District of Missouri. 3 level. Each of the eight product-tampering single-count groups received one unit apiece because they were equally serious. See USSG § 3D1.4(a). The group containing the twelve adulterating/misbranding counts received no units because it was nine or more levels less serious than the product-tampering groups. See USSG § 3D1.4(c). Although there were eight units, the grouping rules apply a flat five-level offense-level increase regardless of how many more than five units there are. See USSG § 3D1.4. Courtney’s highest offense level was thus increased by five levels, bringing his combined offense level to forty. He received a three-level reduction for acceptance of responsibility, see USSG § 3E1.1, making his total final adjusted offense level thirty-seven. With a Category I criminal history, his Guidelines imprisonment range was 210-262 months.

The district court departed upward by three offense levels to level forty, which carries a Guidelines imprisonment range of 292-365 months, and imposed a 360- month prison sentence within that range. The court justified its upward departure on four grounds: the grouping rules disregarded Courtney’s significant number of additional offenses, Courtney significantly endangered public health, Courtney’s conduct caused extreme psychological injury to his victims, and the Guidelines calculations did not take into account Courtney’s uncharged criminal conduct. The experienced district judge stated that, in his view, any one of the four grounds was sufficient to justify the three-level upward departure.

Courtney appeals the district court’s upward departure. Because we conclude that at least two of the reasons cited by the district court solidly support the three- level upward departure, we affirm.

I.

During the pendency of Courtney’s appeal, the Prosecutorial Remedies and Other Tools to end the Exploitation of Children Today (PROTECT) Act of 2003 was

4 enacted. Prior to the PROTECT Act, we would have reviewed the district court’s departure under a unitary abuse-of-discretion standard. Subsequent to the PROTECT Act, we review de novo whether the factors upon which the district court relied advance the objectives set forth in 18 U.S.C. § 3553(a)(2), are authorized under 18 U.S.C. § 3553(b), and are justified by the facts of the case. See United States v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Williams v. United States
503 U.S. 193 (Supreme Court, 1992)
United States v. Maurice B. Chase, Jr.
894 F.2d 488 (First Circuit, 1990)
United States v. Brian S. Collar
904 F.2d 441 (Eighth Circuit, 1990)
United States v. Craig Randolph Pearson
911 F.2d 186 (Ninth Circuit, 1990)
United States v. Donald Wayne Yellow
18 F.3d 1438 (Eighth Circuit, 1994)
United States v. Robert Dee Okane
52 F.3d 828 (Tenth Circuit, 1995)
United States v. Laurence Robert Otto
64 F.3d 367 (Eighth Circuit, 1995)
United States v. John MacLeod
80 F.3d 860 (Third Circuit, 1996)
United States v. Kevin Patrick Szabo
176 F.3d 930 (Seventh Circuit, 1999)
United States v. Barbara Lynn Lewis
235 F.3d 394 (Eighth Circuit, 2000)
United States v. William Douglas Hampton
260 F.3d 832 (Eighth Circuit, 2001)
United States v. Donald A. Wolfe
309 F.3d 932 (Sixth Circuit, 2002)
United States v. Tyrell Vincent Thin Elk
321 F.3d 704 (Eighth Circuit, 2003)
United States v. Mingo Flores
336 F.3d 760 (Eighth Circuit, 2003)
United States v. Courtney
240 F. Supp. 2d 1052 (W.D. Missouri, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Robert Ray Courtney, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-robert-ray-courtney-ca8-2004.